Teva: Our Biosimilars Strategy Has Been Fragmented, We Want To Be Global
Israeli Firm ‘Absolutely’ Believes Biosimilars Are Long-Term Growth Driver
Months into the job, Teva CEO Richard Francis delivered the company’s promise for a new dedicated strategy to return to growth. Funded by a portion of capital reallocated from Teva’s generics business to focus on innovative brands, the new strategy will continue to promote biosimilars, Teva has outlined.
